Respiron is developing an antiviral drug, RN-1, to treat any existing and emerging strains of influenza virus. It can potentially cure flu symptoms in nearly 300 million people worldwide regardless of virus mutation.

Wavetech, LLC is a privately held company specializing in research and development in emerging technology markets. Their emphasis is on electromagnetic technologies, including terahertz, artificial materials, and nondestructive evaluation.

Hyalose specializes in Hyaluronic Acid production and application. The Emergent Technologies Inc. ?Sugar Companies? offer innovative technologies for producing Hyaluronic Acid, heparosan, and chondroitin in a reproducible and safe manner for a variety of medical and aesthetic uses. Hyalose was formed to commercialize unique recombinant technologies for producing Hyaluronic Acid, an important biomolecule for many healthcare and cosmetic applications.

Tetherex is developing a treatment for inflammatory and thrombotic diseases such as Crohn’s disease. Preclinical studies have shown a positive impact in remission of the disease with evidence of potentially reversing the disease process.

GG Companies develops a powerful arthritis rub, a topical herbal gel used to soothe painful areas.

Sensuli, LLC is developing a true once-a-day glucose-responsive insulin that may mimic a healthy human pancreas. Sensulin? may eliminate the need for basal & prandial insulin, offer a substantial improvement in the standard of care, and most importantly, give those with diabetes a chance at a normal life.

The Lupus Multiplex Registry and Repository is finding the genes that cause lupus (also known as SLE or Systemic Lupus erythematosus). It works with families with one or more living lupus patients from across the US, Canada, Puerto Rico and the Virgin Islands, utilizing the genetic link between blood relatives to locate responsible genes.

Charlesson is an ocular pharmaceutical company that is developing therapeutics for various eye diseases, including wet and dry Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Uveitis.

DormaTarg, Inc is a biotechnology company researching and developing therapeutic drugs for cancer recurrence prevention.

EpimedX, LLC is a biotechnology company that was founded in 2011 with the mission to develop Gene Regulation Therapy? ? a promising technology that is expected to provide a safe, cost-effective, and permanent treatment for sickle cell disease, beta-thalassemia, and malaria without dangerous or harmful side effects.

Advance Research Chemicals, Inc. offers basic and advanced chemical applications and services in a wide array of industries including military defense,?semiconductors, battery materials, pharmaceuticals, medical devices, automotive components, textiles, agricultural solutions, surfactants and industrial cleaners.

Cytovance? Biologics adds significant value to biopharmaceutical development programs assisting companies to advance recombinant protein, antibody and cell-based therapeutic products rapidly and cost-effectively from the laboratory bench, through clinical development and to commercial launch in international markets.

COARE Biotechnology is a research driven pharmaceutical company dedicated to developing novel therapeutic agents designed to treat solid tumor cancers.

Astellas is an international pharmaceutical company intensely focused on five key therapeutic areas: cardiology, dermatology, immunology, infectious disease, and urology.

Cosmetic Specialty Labs is skilled in developing high end, prestige skin care products, as well as custom formulated over the counter drugs.

Leviathan proposes a next-generation tool that will make it possible to distinguish and examine heterogeneous states among suspension cells in situ, with the potential for a significant increase in sensitivity, selectivity, resolution, and scalability over current technology.

A subsidiary of Core Oncology, Mills Biopharmaceuticals, LLC (Mills) manufactures ProstaSeed? Iodine 125 brachytherapy seeds for the treatment of prostate cancer. Mills’ state-of-the-art 25,000 square foot manufacturing facility features highly automated machines and advanced manufacturing systems.

Heparinex is a biotechnology company focused on the development of novel recombinant synthesis of heparinoid compounds for various markets including anticoagulation, biomaterials, and cellular modulation applications.

Synereca Pharmaceuticals addresses the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.

Pure MHC focuses on HLA related immunology tools for vaccine development and immunotherapy validation.